{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T06:26:12Z","timestamp":1787293572707,"version":"build-2736575974"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Suleyman Demirel University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Introduction: Obesity is a chronic, multifactorial condition which is a global health challenge. In general, obesity is defined by excessive fat accumulation and associated with the risk of numerous conditions, including type 2 diabetes mellitus (T2DM), cardiovascular disease, heart failure, and metabolic dysfunction-associated steatotic liver disease, and some types of cancer contributing to increased morbidity and mortality. Mineralocorticoid receptor antagonists (MRAs) are used for a long time for management of cardiovascular disease and non-steroidal MRAs also showed kidney protection. Apart from these, there is growing literature showing that MRAs effecting fat mass and fat metabolism. In this review, we summarised the effects of MRAs on fat mass and fat metabolism.<\/jats:p>\n                  <jats:p>Results:In general, studies showed that MRAs reduced fat mass in various organs which is associated decreased oxidative stress, inflammation, and insulin resistance. Importantly, MRAs increased adipose tissue browning and decrease white adipose tissue mass. Up to now, the studies showed no safety signals and these favorable effects are independent of blood pressure reduction. Discussion A part from hemodynamic effects, MRAs have beneficial impacts on fat mass and fat metabolism. Currently, the underlying mechanisms for these effects are not clear<\/jats:p>\n                  <jats:p>Conclusions: Preliminary studies have shown that MRAs have favorable impact on fat metabolism and fat mass. Studies needed to highlight underlying mechanisms..<\/jats:p>","DOI":"10.1007\/s40618-026-02909-0","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T04:35:02Z","timestamp":1779424502000},"page":"2205-2218","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The impact of mineralocorticoid receptor antagonists on fat mass and fat metabolism"],"prefix":"10.1007","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1369-3657","authenticated-orcid":false,"given":"Baris","family":"Afsar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rengin Elsurer","family":"Afsar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geetha","family":"Maddukuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,22]]},"reference":[{"key":"2909_CR1","doi-asserted-by":"publisher","first-page":"3427","DOI":"10.2147\/dmso.S540103","volume":"18","author":"L Wang","year":"2025","unstructured":"Wang L, Wang Q, Xiong Y, Shi W, Qi X (2025) Obesity and its comorbidities: current treatment options, emerging biological mechanisms, future perspectives and challenges. Diabetes Metab Syndr Obes 18:3427\u20133445. https:\/\/doi.org\/10.2147\/dmso.S540103","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"1","key":"2909_CR2","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2025.2521433","volume":"57","author":"RF Kushner","year":"2025","unstructured":"Kushner RF, Shapiro M (2025) Obesity: assessment and treatment across the care continuum. Ann Med 57(1):2521433. https:\/\/doi.org\/10.1080\/07853890.2025.2521433","journal-title":"Ann Med"},{"issue":"20","key":"2909_CR3","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1001\/jama.2023.19897","volume":"330","author":"A Elmaleh-Sachs","year":"2023","unstructured":"Elmaleh-Sachs A, Schwartz JL, Bramante CT, Nicklas JM, Gudzune KA, Jay M (2023) Obesity management in adults: a review. JAMA 330(20):2000\u20132015. https:\/\/doi.org\/10.1001\/jama.2023.19897","journal-title":"JAMA"},{"key":"2909_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26178544","author":"M Olivares-Vicente","year":"2025","unstructured":"Olivares-Vicente M, Herranz-L\u00f3pez M (2025) The interplay between oxidative stress and lipid composition in obesity-induced inflammation: antioxidants as therapeutic agents in metabolic diseases. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms26178544","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2909_CR5","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1093\/cvr\/cvp191","volume":"84","author":"A Hirata","year":"2009","unstructured":"Hirata A, Maeda N, Hiuge A, Hibuse T, Fujita K, Okada T, Kihara S, Funahashi T, Shimomura I (2009) Blockade of mineralocorticoid receptor reverses adipocyte dysfunction and insulin resistance in obese mice. Cardiovasc Res 84(1):164\u2013172. https:\/\/doi.org\/10.1093\/cvr\/cvp191","journal-title":"Cardiovasc Res"},{"key":"2909_CR6","doi-asserted-by":"publisher","first-page":"70","DOI":"10.3389\/fphys.2018.00070","volume":"9","author":"S Hildebrand","year":"2018","unstructured":"Hildebrand S, St\u00fcmer J, Pfeifer A (2018) PVAT and its relation to brown, beige, and white adipose tissue in development and function. Front Physiol 9:70. https:\/\/doi.org\/10.3389\/fphys.2018.00070","journal-title":"Front Physiol"},{"issue":"7","key":"2909_CR7","doi-asserted-by":"publisher","first-page":"2566","DOI":"10.1210\/jc.2008-0251","volume":"93","author":"GP Rossi","year":"2008","unstructured":"Rossi GP, Belfiore A, Bernini G, Fabris B, Caridi G, Ferri C, Giacchetti G, Letizia C, Maccario M, Mannelli M, Palumbo G, Patalano A, Rizzoni D, Rossi E, Pessina AC, Mantero F (2008) Body mass index predicts plasma aldosterone concentrations in overweight-obese primary hypertensive patients. J Clin Endocrinol Metab 93(7):2566\u20132571. https:\/\/doi.org\/10.1210\/jc.2008-0251","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2909_CR8","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1161\/hypertensionaha.116.07806","volume":"68","author":"T Dudenbostel","year":"2016","unstructured":"Dudenbostel T, Ghazi L, Liu M, Li P, Oparil S, Calhoun DA (2016) Body mass index predicts 24-hour urinary aldosterone levels in patients with resistant hypertension. Hypertension 68(4):995\u20131003. https:\/\/doi.org\/10.1161\/hypertensionaha.116.07806","journal-title":"Hypertension"},{"issue":"4","key":"2909_CR9","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1055\/s-0035-1559769","volume":"48","author":"G Iacobellis","year":"2016","unstructured":"Iacobellis G, Petramala L, Marinelli C, Calvieri C, Zinnamosca L, Concistr\u00e8 A, Iannucci G, De Toma G, Letizia C (2016) Epicardial fat thickness and primary aldosteronism. Horm Metab Res 48(4):238\u2013241. https:\/\/doi.org\/10.1055\/s-0035-1559769","journal-title":"Horm Metab Res"},{"issue":"1","key":"2909_CR10","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s12902-020-00654-w","volume":"20","author":"W Manosroi","year":"2020","unstructured":"Manosroi W, Atthakomol P (2020) High body fat percentage is associated with primary aldosteronism: a cross-sectional study. BMC Endocr Disord 20(1):175. https:\/\/doi.org\/10.1186\/s12902-020-00654-w","journal-title":"BMC Endocr Disord"},{"issue":"11","key":"2909_CR11","doi-asserted-by":"publisher","first-page":"4472","DOI":"10.1210\/jc.2007-1088","volume":"92","author":"R Bentley-Lewis","year":"2007","unstructured":"Bentley-Lewis R, Adler GK, Perlstein T, Seely EW, Hopkins PN, Williams GH, Garg R (2007) Body mass index predicts aldosterone production in normotensive adults on a high-salt diet. J Clin Endocrinol Metab 92(11):4472\u20134475. https:\/\/doi.org\/10.1210\/jc.2007-1088","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2909_CR12","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1161\/circulationaha.107.708537","volume":"116","author":"E Ingelsson","year":"2007","unstructured":"Ingelsson E, Pencina MJ, Tofler GH, Benjamin EJ, Lanier KJ, Jacques PF, Fox CS, Meigs JB, Levy D, Larson MG, Selhub J, D\u2019Agostino RB Sr., Wang TJ, Vasan RS (2007) Multimarker approach to evaluate the incidence of the metabolic syndrome and longitudinal changes in metabolic risk factors: the Framingham Offspring Study. Circulation 116(9):984\u2013992. https:\/\/doi.org\/10.1161\/circulationaha.107.708537","journal-title":"Circulation"},{"issue":"10","key":"2909_CR13","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1038\/hr.2013.45","volume":"36","author":"JN Cooper","year":"2013","unstructured":"Cooper JN, Fried L, Tepper P, Barinas-Mitchell E, Conroy MB, Evans RW, Mori Brooks M, Woodard GA, Sutton-Tyrrell K (2013) Changes in serum aldosterone are associated with changes in obesity-related factors in normotensive overweight and obese young adults. Hypertens Res 36(10):895\u2013901. https:\/\/doi.org\/10.1038\/hr.2013.45","journal-title":"Hypertens Res"},{"issue":"12","key":"2909_CR14","doi-asserted-by":"publisher","first-page":"3438","DOI":"10.1681\/asn.2006080944","volume":"17","author":"M Nagase","year":"2006","unstructured":"Nagase M, Yoshida S, Shibata S, Nagase T, Gotoda T, Ando K, Fujita T (2006) Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: possible contribution of fat-derived factors. J Am Soc Nephrol 17(12):3438\u20133446. https:\/\/doi.org\/10.1681\/asn.2006080944","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"2909_CR15","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1161\/hypertensionaha.111.190223","volume":"59","author":"AM Briones","year":"2012","unstructured":"Briones AM, Nguyen Dinh Cat A, Callera GE, Yogi A, Burger D, He Y, Corr\u00eaa JW, Gagnon AM, Gomez-Sanchez CE, Gomez-Sanchez EP, Sorisky A, Ooi TC, Ruzicka M, Burns KD, Touyz RM (2012) Adipocytes produce aldosterone through calcineurin-dependent signaling pathways: implications in diabetes mellitus-associated obesity and vascular dysfunction. Hypertension 59(5):1069\u20131078. https:\/\/doi.org\/10.1161\/hypertensionaha.111.190223","journal-title":"Hypertension"},{"key":"2909_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.00223","volume":"11","author":"A Vecchiola","year":"2020","unstructured":"Vecchiola A, Fuentes CA, Solar I, Lagos CF, Opazo MC, Mu\u00f1oz-Durango N, Riedel CA, Owen GI, Kalergis AM, Fardella CE (2020) Eplerenone implantation improved adipose dysfunction averting RAAS activation and cell division. Front Endocrinol (Lausanne) 11:223. https:\/\/doi.org\/10.3389\/fendo.2020.00223","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"2909_CR17","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1530\/joe-17-0351","volume":"235","author":"T Wada","year":"2017","unstructured":"Wada T, Ishikawa A, Watanabe E, Nakamura Y, Aruga Y, Hasegawa H, Onogi Y, Honda H, Nagai Y, Takatsu K, Ishii Y, Sasahara M, Koya D, Tsuneki H, Sasaoka T (2017) Eplerenone prevented obesity-induced inflammasome activation and glucose intolerance. J Endocrinol 235(3):179\u2013191. https:\/\/doi.org\/10.1530\/joe-17-0351","journal-title":"J Endocrinol"},{"issue":"2","key":"2909_CR18","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1161\/hypertensionaha.108.121954","volume":"53","author":"Y Wei","year":"2009","unstructured":"Wei Y, Whaley-Connell AT, Habibi J, Rehmer J, Rehmer N, Patel K, Hayden M, DeMarco V, Ferrario CM, Ibdah JA, Sowers JR (2009) Mineralocorticoid receptor antagonism attenuates vascular apoptosis and injury via rescuing protein kinase B activation. Hypertension 53(2):158\u2013165. https:\/\/doi.org\/10.1161\/hypertensionaha.108.121954","journal-title":"Hypertension"},{"issue":"8","key":"2909_CR19","doi-asserted-by":"publisher","first-page":"3745","DOI":"10.1096\/fj.13-245415","volume":"28","author":"A Armani","year":"2014","unstructured":"Armani A, Cinti F, Marzolla V, Morgan J, Cranston GA, Antelmi A, Carpinelli G, Canese R, Pagotto U, Quarta C, Malorni W, Matarrese P, Marconi M, Fabbri A, Rosano G, Cinti S, Young MJ, Caprio M (2014) Mineralocorticoid receptor antagonism induces browning of white adipose tissue through impairment of autophagy and prevents adipocyte dysfunction in high-fat-diet-fed mice. FASEB J 28(8):3745\u20133757. https:\/\/doi.org\/10.1096\/fj.13-245415","journal-title":"FASEB J"},{"issue":"3","key":"2909_CR20","doi-asserted-by":"publisher","first-page":"R253","DOI":"10.1152\/ajpregu.00316.2021","volume":"322","author":"J Habibi","year":"2022","unstructured":"Habibi J, Chen D, Hulse JL, Whaley-Connell A, Sowers JR, Jia G (2022) Targeting mineralocorticoid receptors in diet-induced hepatic steatosis and insulin resistance. Am J Physiol Regul Integr Comp Physiol 322(3):R253\u2013R262. https:\/\/doi.org\/10.1152\/ajpregu.00316.2021","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"issue":"11","key":"2909_CR21","doi-asserted-by":"publisher","first-page":"E1415","DOI":"10.1152\/ajpendo.00419.2013","volume":"305","author":"T Wada","year":"2013","unstructured":"Wada T, Miyashita Y, Sasaki M, Aruga Y, Nakamura Y, Ishii Y, Sasahara M, Kanasaki K, Kitada M, Koya D, Shimano H, Tsuneki H, Sasaoka T (2013) Eplerenone ameliorates the phenotypes of metabolic syndrome with NASH in liver-specific SREBP-1c Tg mice fed high-fat and high-fructose diet. Am J Physiol Endocrinol Metab 305(11):E1415\u2013E1425. https:\/\/doi.org\/10.1152\/ajpendo.00419.2013","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"9","key":"2909_CR22","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1111\/liv.12794","volume":"35","author":"M Pizarro","year":"2015","unstructured":"Pizarro M, Sol\u00eds N, Quintero P, Barrera F, Cabrera D, Rojas-de Santiago P, Arab JP, Padilla O, Roa JC, Moshage H, Wree A, Inzaugarat E, Feldstein AE, Fardella CE, Baudrand R, Riquelme A, Arrese M (2015) Beneficial effects of mineralocorticoid receptor blockade in experimental non-alcoholic steatohepatitis. Liver Int 35(9):2129\u20132138. https:\/\/doi.org\/10.1111\/liv.12794","journal-title":"Liver Int"},{"issue":"5","key":"2909_CR23","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1536\/ihj.25-051","volume":"66","author":"J Maeda","year":"2025","unstructured":"Maeda J, Munkhjargal U, Hara T, Bavuu O, Fukuda D, Sata M (2025) Esaxerenone attenuates atherogenesis and vascular dysfunction in Apolipoprotein E-deficient mice. Int Heart J 66(5):895\u2013903. https:\/\/doi.org\/10.1536\/ihj.25-051","journal-title":"Int Heart J"},{"key":"2909_CR24","doi-asserted-by":"publisher","DOI":"10.1210\/endocr\/bqac145","author":"JL Hulse","year":"2022","unstructured":"Hulse JL, Habibi J, Igbekele AE, Zhang B, Li J, Whaley-Connell A, Sowers JR, Jia G (2022) Mineralocorticoid receptors mediate diet-induced lipid infiltration of skeletal muscle and insulin resistance. Endocrinology. https:\/\/doi.org\/10.1210\/endocr\/bqac145","journal-title":"Endocrinology"},{"key":"2909_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2840-12-172","volume":"12","author":"E Ram\u00edrez","year":"2013","unstructured":"Ram\u00edrez E, Klett-Mingo M, Ares-Carrasco S, Picatoste B, Ferrarini A, Rup\u00e9rez FJ, Caro-Vadillo A, Barbas C, Egido J, Tu\u00f1\u00f3n J, Lorenzo \u00d3 (2013) Eplerenone attenuated cardiac steatosis, apoptosis and diastolic dysfunction in experimental type-II diabetes. Cardiovasc Diabetol 12:172. https:\/\/doi.org\/10.1186\/1475-2840-12-172","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"2909_CR26","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s40618-021-01635-z","volume":"45","author":"V Marzolla","year":"2022","unstructured":"Marzolla V, Feraco A, Limana F, Kolkhof P, Armani A, Caprio M (2022) Class-specific responses of brown adipose tissue to steroidal and nonsteroidal mineralocorticoid receptor antagonists. J Endocrinol Invest 45(1):215\u2013220. https:\/\/doi.org\/10.1007\/s40618-021-01635-z","journal-title":"J Endocrinol Invest"},{"issue":"12","key":"2909_CR27","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1111\/dom.12989","volume":"19","author":"SA Polyzos","year":"2017","unstructured":"Polyzos SA, Kountouras J, Mantzoros CS, Polymerou V, Katsinelos P (2017) Effects of combined low-dose spironolactone plus vitamin E vs vitamin E monotherapy on insulin resistance, non-invasive indices of steatosis and fibrosis, and adipokine levels in non-alcoholic fatty liver disease: a randomized controlled trial. Diabetes Obes Metab 19(12):1805\u20131809. https:\/\/doi.org\/10.1111\/dom.12989","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"2909_CR28","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1111\/dom.13809","volume":"21","author":"ML Johansen","year":"2019","unstructured":"Johansen ML, Schou M, Rossignol P, Holm MR, Rasmussen J, Brandt N, Frandsen M, Chabanova E, Dela F, Faber J, Kistorp C (2019) Effect of the mineralocorticoid receptor antagonist eplerenone on liver fat and metabolism in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial (MIRAD trial). Diabetes Obes Metab 21(10):2305\u20132314. https:\/\/doi.org\/10.1111\/dom.13809","journal-title":"Diabetes Obes Metab"},{"key":"2909_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/cells11081264","author":"X Fu","year":"2022","unstructured":"Fu X, Almenglo C, Fernandez \u00c1L, Mart\u00ednez-Cereijo JM, Iglesias-Alvarez D, Duran-Mu\u00f1oz D, Garc\u00eda-Caballero T, Gonzalez-Juanatey JR, Rodriguez-Ma\u00f1ero M, Eiras S (2022) The effect of mineralocorticoid receptor 3 antagonists on anti-inflammatory and anti-fatty acid transport profile in patients with heart failure. Cells. https:\/\/doi.org\/10.3390\/cells11081264","journal-title":"Cells"},{"issue":"3","key":"2909_CR30","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1111\/dom.13539","volume":"21","author":"M Thuzar","year":"2019","unstructured":"Thuzar M, Law WP, Dimeski G, Stowasser M, Ho KKY (2019) Mineralocorticoid antagonism enhances brown adipose tissue function in humans: a randomized placebo-controlled cross-over study. Diabetes Obes Metab 21(3):509\u2013516. https:\/\/doi.org\/10.1111\/dom.13539","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"2909_CR31","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1038\/s41440-021-00836-6","volume":"45","author":"T Ishikawa","year":"2022","unstructured":"Ishikawa T, Morimoto S, Ichihara A (2022) Effects of mineralocorticoid receptor antagonists on sex hormones and body composition in patients with primary aldosteronism. Hypertens Res 45(3):496\u2013506. https:\/\/doi.org\/10.1038\/s41440-021-00836-6","journal-title":"Hypertens Res"},{"issue":"3","key":"2909_CR32","doi-asserted-by":"publisher","first-page":"4589","DOI":"10.3892\/mmr.2018.8386","volume":"17","author":"JJ Zhu","year":"2018","unstructured":"Zhu JJ, Chen YP, Yang M, Liu BL, Dong J, Dong HR, Rui HL, Cheng H (2018) Aldosterone is involved in the pathogenesis of obesity-related glomerulopathy through activation of Wnt\/\u03b2-catenin signaling in podocytes. Mol Med Rep 17(3):4589\u20134598. https:\/\/doi.org\/10.3892\/mmr.2018.8386","journal-title":"Mol Med Rep"},{"issue":"9","key":"2909_CR33","doi-asserted-by":"publisher","first-page":"12450","DOI":"10.1096\/fj.202000164R","volume":"34","author":"V Marzolla","year":"2020","unstructured":"Marzolla V, Feraco A, Gorini S, Mammi C, Marrese C, Mularoni V, Boitani C, Lomb\u00e8s M, Kolkhof P, Ciriolo MR, Armani A, Caprio M (2020) The novel non-steroidal MR antagonist finerenone improves metabolic parameters in high-fat diet-fed mice and activates brown adipose tissue via AMPK-ATGL pathway. FASEB J 34(9):12450\u201312465. https:\/\/doi.org\/10.1096\/fj.202000164R","journal-title":"FASEB J"},{"issue":"5","key":"2909_CR34","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1007\/s00424-025-03066-8","volume":"477","author":"S Hildebrand","year":"2025","unstructured":"Hildebrand S, Pfeifer A (2025) The obesity pandemic and its impact on non-communicable disease burden. Pflugers Arch 477(5):657\u2013668. https:\/\/doi.org\/10.1007\/s00424-025-03066-8","journal-title":"Pflugers Arch"},{"issue":"9","key":"2909_CR35","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1038\/s41591-024-03095-3","volume":"30","author":"L Busetto","year":"2024","unstructured":"Busetto L, Dicker D, Fr\u00fchbeck G, Halford JCG, Sbraccia P, Yumuk V, Goossens GH (2024) A new framework for the diagnosis, staging and management of obesity in adults. Nat Med 30(9):2395\u20132399. https:\/\/doi.org\/10.1038\/s41591-024-03095-3","journal-title":"Nat Med"},{"issue":"10","key":"2909_CR36","doi-asserted-by":"publisher","first-page":"3229","DOI":"10.1038\/s41591-025-03765-w","volume":"31","author":"B McGowan","year":"2025","unstructured":"McGowan B, Ciudin A, Baker JL, Busetto L, Dicker D, Fr\u00fchbeck G, Goossens GH, Monami M, Sbraccia P, Martinez-Tellez B, Woodward E, Yumuk V (2025) Framework for the pharmacological treatment of obesity and its complications from the European Association for the Study of Obesity (EASO). Nat Med 31(10):3229\u20133232. https:\/\/doi.org\/10.1038\/s41591-025-03765-w","journal-title":"Nat Med"},{"issue":"10456","key":"2909_CR37","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1016\/s0140-6736(24)01210-8","volume":"404","author":"I Lingvay","year":"2024","unstructured":"Lingvay I, Cohen RV, Roux CWL, Sumithran P (2024) Obesity in adults. Lancet 404(10456):972\u2013987. https:\/\/doi.org\/10.1016\/s0140-6736(24)01210-8","journal-title":"Lancet"},{"issue":"1","key":"2909_CR38","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s40200-024-01512-5","volume":"24","author":"S Dodangeh","year":"2025","unstructured":"Dodangeh S, Hasani-Ranjbar S (2025) Old and new anti-obesity drugs. J Diabetes Metab Disord 24(1):16. https:\/\/doi.org\/10.1007\/s40200-024-01512-5","journal-title":"J Diabetes Metab Disord"},{"issue":"8","key":"2909_CR39","doi-asserted-by":"publisher","first-page":"879.e871","DOI":"10.1016\/j.amjmed.2016.02.009","volume":"129","author":"HL Daneschvar","year":"2016","unstructured":"Daneschvar HL, Aronson MD, Smetana GW (2016) FDA-approved anti-obesity drugs in the United States. Am J Med 129(8):879.e871\u2013e876. https:\/\/doi.org\/10.1016\/j.amjmed.2016.02.009","journal-title":"Am J Med"},{"issue":"11","key":"2909_CR40","doi-asserted-by":"publisher","first-page":"6116","DOI":"10.1111\/dom.70019","volume":"27","author":"M Guldan","year":"2025","unstructured":"Guldan M, Ozbek L, Abdel-Rahman SM, Narin AE, Orak HI, Goren HK, Afsar B, Rossing P, Kanbay M (2025) Targeting visceral and ectopic adiposity: pharmacological and surgical interventions beyond global weight loss. Diabetes Obes Metab 27(11):6116\u20136138. https:\/\/doi.org\/10.1111\/dom.70019","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"2909_CR41","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1007\/s11886-023-01998-0","volume":"25","author":"U Kintscher","year":"2023","unstructured":"Kintscher U (2023) Cardiovascular and renal benefit of novel non-steroidal mineralocorticoid antagonists in patients with diabetes. Curr Cardiol Rep 25(12):1859\u20131864. https:\/\/doi.org\/10.1007\/s11886-023-01998-0","journal-title":"Curr Cardiol Rep"},{"issue":"2","key":"2909_CR42","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","volume":"42","author":"R Agarwal","year":"2021","unstructured":"Agarwal R, Kolkhof P, Bakris G, Bauersachs J, Haller H, Wada T, Zannad F (2021) Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. Eur Heart J 42(2):152\u2013161. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa736","journal-title":"Eur Heart J"},{"issue":"9","key":"2909_CR43","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1001\/jama.2015.10081","volume":"314","author":"GL Bakris","year":"2015","unstructured":"Bakris GL, Agarwal R, Chan JC, Cooper ME, Gansevoort RT, Haller H, Remuzzi G, Rossing P, Schmieder RE, Nowack C, Kolkhof P, Joseph A, Pieper A, Kimmeskamp-Kirschbaum N, Ruilope LM (2015) Effect of Finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial. JAMA 314(9):884\u2013894. https:\/\/doi.org\/10.1001\/jama.2015.10081","journal-title":"JAMA"},{"issue":"6","key":"2909_CR44","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1161\/circulationaha.120.051898","volume":"143","author":"G Filippatos","year":"2021","unstructured":"Filippatos G, Anker SD, Agarwal R, Pitt B, Ruilope LM, Rossing P, Kolkhof P, Schloemer P, Tornus I, Joseph A, Bakris GL (2021) Finerenone and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes. Circulation 143(6):540\u2013552. https:\/\/doi.org\/10.1161\/circulationaha.120.051898","journal-title":"Circulation"},{"issue":"23","key":"2909_CR45","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, Kolkhof P, Nowack C, Schloemer P, Joseph A, Filippatos G (2020) Effect of Finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med 383(23):2219\u20132229. https:\/\/doi.org\/10.1056\/NEJMoa2025845","journal-title":"N Engl J Med"},{"issue":"24","key":"2909_CR46","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","volume":"385","author":"B Pitt","year":"2021","unstructured":"Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, Joseph A, Kolkhof P, Nowack C, Schloemer P, Ruilope LM (2021) Cardiovascular events with Finerenone in kidney disease and type 2 diabetes. N Engl J Med 385(24):2252\u20132263. https:\/\/doi.org\/10.1056\/NEJMoa2110956","journal-title":"N Engl J Med"},{"issue":"12","key":"2909_CR47","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.7326\/m23-1023","volume":"176","author":"R Agarwal","year":"2023","unstructured":"Agarwal R, Tu W, Farjat AE, Farag YMK, Toto R, Kaul S, Lawatscheck R, Rohwedder K, Ruilope LM, Rossing P, Pitt B, Filippatos G, Anker SD, Bakris GL (2023) Impact of Finerenone-induced albuminuria reduction on chronic kidney disease outcomes in type 2 diabetes: a mediation analysis. Ann Intern Med 176(12):1606\u20131616. https:\/\/doi.org\/10.7326\/m23-1023","journal-title":"Ann Intern Med"},{"issue":"2","key":"2909_CR48","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.jacc.2024.10.091","volume":"85","author":"FR Mc Causland","year":"2025","unstructured":"Mc Causland FR, Vaduganathan M, Claggett BL, Kulac IJ, Desai AS, Jhund PS, Henderson AD, Brinker M, Perkins R, Scheerer MF, Schloemer P, Lam CSP, Senni M, Shah SJ, Voors AA, Zannad F, Pitt B, McMurray JJV, Solomon SD (2025) Finerenone and kidney outcomes in patients with heart failure: The FINEARTS-HF trial. J Am Coll Cardiol 85(2):159\u2013168. https:\/\/doi.org\/10.1016\/j.jacc.2024.10.091","journal-title":"J Am Coll Cardiol"},{"issue":"24","key":"2909_CR49","doi-asserted-by":"publisher","first-page":"14211","DOI":"10.1073\/pnas.2336140100","volume":"100","author":"M Ehrhart-Bornstein","year":"2003","unstructured":"Ehrhart-Bornstein M, Lamounier-Zepter V, Schraven A, Langenbach J, Willenberg HS, Barthel A, Hauner H, McCann SM, Scherbaum WA, Bornstein SR (2003) Human adipocytes secrete mineralocorticoid-releasing factors. Proc Natl Acad Sci U S A 100(24):14211\u201314216. https:\/\/doi.org\/10.1073\/pnas.2336140100","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2909_CR50","doi-asserted-by":"publisher","first-page":"F7","DOI":"10.1530\/jme-16-0025","volume":"57","author":"AN Dinh Cat","year":"2016","unstructured":"Dinh Cat AN, Friederich-Persson M, White A, Touyz RM (2016) Adipocytes, aldosterone and obesity-related hypertension. J Mol Endocrinol 57(1):F7\u2013F21. https:\/\/doi.org\/10.1530\/jme-16-0025","journal-title":"J Mol Endocrinol"},{"issue":"5","key":"2909_CR51","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1210\/en.2009-0869","volume":"151","author":"T Wada","year":"2010","unstructured":"Wada T, Kenmochi H, Miyashita Y, Sasaki M, Ojima M, Sasahara M, Koya D, Tsuneki H, Sasaoka T (2010) Spironolactone improves glucose and lipid metabolism by ameliorating hepatic steatosis and inflammation and suppressing enhanced gluconeogenesis induced by high-fat and high-fructose diet. Endocrinology 151(5):2040\u20132049. https:\/\/doi.org\/10.1210\/en.2009-0869","journal-title":"Endocrinology"},{"issue":"1","key":"2909_CR52","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1161\/hypertensionaha.114.04981","volume":"66","author":"R Urbanet","year":"2015","unstructured":"Urbanet R, Nguyen Dinh Cat A, Feraco A, Venteclef N, El Mogrhabi S, Sierra-Ramos C, Alvarez de la Rosa D, Adler GK, Quilliot D, Rossignol P, Fallo F, Touyz RM, Jaisser F (2015) Adipocyte mineralocorticoid receptor activation leads to metabolic syndrome and induction of prostaglandin D2 synthase. Hypertension 66(1):149\u2013157. https:\/\/doi.org\/10.1161\/hypertensionaha.114.04981","journal-title":"Hypertension"},{"issue":"12","key":"2909_CR53","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1111\/jch.14898","volume":"26","author":"H Puzantian","year":"2024","unstructured":"Puzantian H, Townsend R, Bansal S (2024) Obesity, aldosterone excess, and mineralocorticoid receptor activation: parallel or intersected circumstances? J Clin Hypertens (Greenwich) 26(12):1384\u20131390. https:\/\/doi.org\/10.1111\/jch.14898","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"1","key":"2909_CR54","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00441-025-04029-2","volume":"403","author":"E P\u00e9rez-S\u00e1nchez","year":"2026","unstructured":"P\u00e9rez-S\u00e1nchez E, S\u00e1nchez-Sol\u00eds CN, Morimoto S, Corona-P\u00e9rez A, Mart\u00ednez-G\u00f3mez M, Rodr\u00edguez-Antol\u00edn J, Cuevas-Romero E, Nicol\u00e1s-Toledo L (2026) Aldosterone induced by chronic stress promotes pancreatic steatosis in young male rats. Cell Tissue Res 403(1):3. https:\/\/doi.org\/10.1007\/s00441-025-04029-2","journal-title":"Cell Tissue Res"},{"issue":"1\u20132","key":"2909_CR55","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.mce.2009.08.015","volume":"318","author":"BR Thompson","year":"2010","unstructured":"Thompson BR, Lobo S, Bernlohr DA (2010) Fatty acid flux in adipocytes: the in\u2019s and out\u2019s of fat cell lipid trafficking. Mol Cell Endocrinol 318(1\u20132):24\u201333. https:\/\/doi.org\/10.1016\/j.mce.2009.08.015","journal-title":"Mol Cell Endocrinol"},{"issue":"5","key":"2909_CR56","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1073\/pnas.96.5.2391","volume":"96","author":"YT Zhou","year":"1999","unstructured":"Zhou YT, Wang ZW, Higa M, Newgard CB, Unger RH (1999) Reversing adipocyte differentiation: implications for treatment of obesity. Proc Natl Acad Sci U S A 96(5):2391\u20132395. https:\/\/doi.org\/10.1073\/pnas.96.5.2391","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"2909_CR57","doi-asserted-by":"publisher","first-page":"C853","DOI":"10.1152\/ajpcell.00331.2001","volume":"282","author":"F Machinal-Qu\u00e9lin","year":"2002","unstructured":"Machinal-Qu\u00e9lin F, Dieudonn\u00e9 MN, Leneveu MC, Pecquery R, Giudicelli Y (2002) Proadipogenic effect of leptin on rat preadipocytes in vitro: activation of MAPK and STAT3 signaling pathways. Am J Physiol Cell Physiol 282(4):C853\u2013C863. https:\/\/doi.org\/10.1152\/ajpcell.00331.2001","journal-title":"Am J Physiol Cell Physiol"},{"key":"2909_CR58","doi-asserted-by":"publisher","first-page":"841","DOI":"10.3389\/fendo.2019.00841","volume":"10","author":"L Palhinha","year":"2019","unstructured":"Palhinha L, Liechocki S, Hottz ED, Pereira J, de Almeida CJ, Moraes-Vieira PMM, Bozza PT, Maya-Monteiro CM (2019) Leptin induces proadipogenic and proinflammatory signaling in adipocytes. Front Endocrinol (Lausanne) 10:841. https:\/\/doi.org\/10.3389\/fendo.2019.00841","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"2909_CR59","doi-asserted-by":"publisher","first-page":"R1557","DOI":"10.1152\/ajpregu.00860.2005","volume":"290","author":"B Wagoner","year":"2006","unstructured":"Wagoner B, Hausman DB, Harris RB (2006) Direct and indirect effects of leptin on preadipocyte proliferation and differentiation. Am J Physiol Regul Integr Comp Physiol 290(6):R1557\u2013R1564. https:\/\/doi.org\/10.1152\/ajpregu.00860.2005","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"issue":"9","key":"2909_CR60","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.2527\/2005.8392066x","volume":"83","author":"TG Ramsay","year":"2005","unstructured":"Ramsay TG (2005) Porcine preadipocyte proliferation and differentiation: a role for leptin? J Anim Sci 83(9):2066\u20132074. https:\/\/doi.org\/10.2527\/2005.8392066x","journal-title":"J Anim Sci"},{"issue":"1","key":"2909_CR61","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s11154-021-09687-5","volume":"23","author":"C Pic\u00f3","year":"2022","unstructured":"Pic\u00f3 C, Palou M, Pomar CA, Rodr\u00edguez AM, Palou A (2022) Leptin as a key regulator of the adipose organ. Rev Endocr Metab Disord 23(1):13\u201330. https:\/\/doi.org\/10.1007\/s11154-021-09687-5","journal-title":"Rev Endocr Metab Disord"},{"key":"2909_CR62","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15253","volume":"8","author":"KL Spalding","year":"2017","unstructured":"Spalding KL, Bernard S, N\u00e4slund E, Salehpour M, Possnert G, Appelsved L, Fu KY, Alkass K, Druid H, Thorell A, Ryd\u00e9n M, Arner P (2017) Impact of fat mass and distribution on lipid turnover in human adipose tissue. Nat Commun 8:15253. https:\/\/doi.org\/10.1038\/ncomms15253","journal-title":"Nat Commun"},{"issue":"2","key":"2909_CR63","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s11154-023-09850-0","volume":"25","author":"Z Ghesmati","year":"2024","unstructured":"Ghesmati Z, Rashid M, Fayezi S, Gieseler F, Alizadeh E, Darabi M (2024) An update on the secretory functions of brown, white, and beige adipose tissue: towards therapeutic applications. Rev Endocr Metab Disord 25(2):279\u2013308. https:\/\/doi.org\/10.1007\/s11154-023-09850-0","journal-title":"Rev Endocr Metab Disord"},{"issue":"2","key":"2909_CR64","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.mce.2009.08.018","volume":"316","author":"S Galic","year":"2010","unstructured":"Galic S, Oakhill JS, Steinberg GR (2010) Adipose tissue as an endocrine organ. Mol Cell Endocrinol 316(2):129\u2013139. https:\/\/doi.org\/10.1016\/j.mce.2009.08.018","journal-title":"Mol Cell Endocrinol"},{"key":"2909_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2025.156239","volume":"168","author":"A Ribas-Latre","year":"2025","unstructured":"Ribas-Latre A, Hoffmann A, Gebhardt C, Weiner J, Arndt L, Raulien N, Gericke M, Ghosh A, Krause K, Kl\u00f6ting N, Pfluger PT, Sheikh BN, Ebert T, T\u00f6njes A, Stumvoll M, Wolfrum C, Bl\u00fcher M, Wagner U, Vendrell J, Fern\u00e1ndez-Veledo S, Heiker JT (2025) The serine protease KLK7 promotes immune cell infiltration in visceral adipose tissue in obesity. Metabolism 168:156239. https:\/\/doi.org\/10.1016\/j.metabol.2025.156239","journal-title":"Metabolism"},{"issue":"6","key":"2909_CR66","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.1073\/pnas.1920004117","volume":"117","author":"MS Han","year":"2020","unstructured":"Han MS, White A, Perry RJ, Camporez JP, Hidalgo J, Shulman GI, Davis RJ (2020) Regulation of adipose tissue inflammation by interleukin 6. Proc Natl Acad Sci U S A 117(6):2751\u20132760. https:\/\/doi.org\/10.1073\/pnas.1920004117","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"2909_CR67","doi-asserted-by":"publisher","first-page":"R243","DOI":"10.1530\/eje-20-1439","volume":"184","author":"BT McNeill","year":"2021","unstructured":"McNeill BT, Suchacki KJ, Stimson RH (2021) Mechanisms in endocrinology: human brown adipose tissue as a therapeutic target: warming up or cooling down? Eur J Endocrinol 184(6):R243\u2013R259. https:\/\/doi.org\/10.1530\/eje-20-1439","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2909_CR68","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41556-023-01311-9","volume":"26","author":"L Reverte-Salisa","year":"2024","unstructured":"Reverte-Salisa L, Siddig S, Hildebrand S, Yao X, Zurkovic J, Jaeckstein MY, Heeren J, Lezoualc\u2019h F, Krahmer N, Pfeifer A (2024) EPAC1 enhances brown fat growth and beige adipogenesis. Nat Cell Biol 26(1):113\u2013123. https:\/\/doi.org\/10.1038\/s41556-023-01311-9","journal-title":"Nat Cell Biol"},{"key":"2909_CR69","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1065263","volume":"13","author":"X Liu","year":"2022","unstructured":"Liu X, Zhang Z, Song Y, Xie H, Dong M (2022) An update on brown adipose tissue and obesity intervention: function, regulation and therapeutic implications. Front Endocrinol (Lausanne) 13:1065263. https:\/\/doi.org\/10.3389\/fendo.2022.1065263","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"2909_CR70","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3594","volume":"39","author":"E Harb","year":"2023","unstructured":"Harb E, Kheder O, Poopalasingam G, Rashid R, Srinivasan A, Izzi-Engbeaya C (2023) Brown adipose tissue and regulation of human body weight. Diabetes Metab Res Rev 39(1):e3594. https:\/\/doi.org\/10.1002\/dmrr.3594","journal-title":"Diabetes Metab Res Rev"},{"issue":"3","key":"2909_CR71","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.cell.2021.12.016","volume":"185","author":"A Sakers","year":"2022","unstructured":"Sakers A, De Siqueira MK, Seale P, Villanueva CJ (2022) Adipose-tissue plasticity in health and disease. Cell 185(3):419\u2013446. https:\/\/doi.org\/10.1016\/j.cell.2021.12.016","journal-title":"Cell"},{"issue":"1","key":"2909_CR72","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s13098-023-01064-3","volume":"15","author":"T Jin","year":"2023","unstructured":"Jin T, Fu X, Liu M, An F (2023) Finerenone attenuates myocardial apoptosis, metabolic disturbance and myocardial fibrosis in type 2 diabetes mellitus. Diabetol Metab Syndr 15(1):87. https:\/\/doi.org\/10.1186\/s13098-023-01064-3","journal-title":"Diabetol Metab Syndr"},{"issue":"12","key":"2909_CR73","doi-asserted-by":"publisher","first-page":"3244","DOI":"10.1038\/s41440-025-02401-x","volume":"48","author":"R Mitsuno","year":"2025","unstructured":"Mitsuno R, Nakamura T, Nakamura K, Kaneko K, Kojima D, Mizutani Y, Yamada Y, Jinzaki M, Azegami T, Kanda T, Kinouchi K, Itoh H, Yoshino J, Hayashi K (2025) Effects of perirenal fat accumulation on cardiometabolic and renal functions and mineralocorticoid receptor activation in primary aldosteronism. Hypertens Res 48(12):3244\u20133256. https:\/\/doi.org\/10.1038\/s41440-025-02401-x","journal-title":"Hypertens Res"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-026-02909-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-026-02909-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-026-02909-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T06:08:37Z","timestamp":1787292517000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-026-02909-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,22]]},"references-count":73,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["2909"],"URL":"https:\/\/doi.org\/10.1007\/s40618-026-02909-0","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,22]]},"assertion":[{"value":"17 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}